- Home
- » Tags
- » Preladenant
Top View
- Adenosine Receptor P1 Receptor
- Research in Your Backyard Developing Cures, Creating Jobs
- Universidade De São Paulo Instituto De Química Héllio
- NIH Public Access Author Manuscript Pharmacol Ther
- Preladenant As an Adjunctive Therapy with Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned
- Title Page Pharmacology and Structure of Isolated Conformations
- Tumor Immunotherapy Using A2A Adenosine Receptor Antagonists
- Preladenant As an Adjunctive Therapy with Levodopa in Parkinson Disease
- Mass Spectrometry Method Development to Identify Binding Ligands Against A2AR Nanodisc Complex
- Dyskinesia in Parkinson's Disease Therapy
- Randomized Trial of Preladenant, Given As Monotherapy, in Patients with Early Parkinson Disease Fabrizio Stocchi, Olivier Rascol, Robert A
- NCT Number: NCT03099161 Document Date: 30-Mar-2017 Product: MK-3814A 1 Protocol/Amendment No.: 062-01
- Merck & Co., Inc. Policy on Posting of Redacted Study Protocols on Journal
- Pharmaabkommen A1 E
- Kelly Mills, MD, MHS Johns Hopkins Parkinson's Disease and Movement
- Purinergic Receptors in Neurological Diseases with Motor Symptoms: Targets for Therapy
- Pharmaceutical Products and Chemical Intermediates, Fourth Review: Advice Concerning the Addition of Certain Products to the Pharmaceutical Appendix to the HTS
- Application of Structure-Based Drug Discovery to G Protein-Coupled Receptors
- Purinergic Receptors of the Central Nervous
- A Role for Adenosine Parsa Ghasem De
- WO 2021/062244 Al 01 April 2021 (01.04.2021) W IP O I PCT
- Anatomical Distribution of Nucleoside System in the Human Brain and Implications for Therapy
- Drug Repurposing Compound Library Plus (96-Well)
- For Peer Review
- Istradefylline to Treat Patients with Parkinson's Disease Experiencing
- Tozadenant (SYN115) in Patients with Parkinson's Disease Who Have
- Purinergic Signalling in Parkinson's Disease: a Multi-Target System To
- Metadata of the Article That Will Be Visualized in Onlinefirst
- Purinergic Mechanisms in Neuroinflammation
- Receptor Characterization and Search for Novel Ligands
- Caffeine and Progression of Parkinson Disease: a Deleterious Interaction with Creatine
- Standouts Melanoma Drug Yervoy, with Seemingly Better Tolerability
- Drug Repurposing Compound Library (96-Well)
- Initial Evaluation of an Adenosine A2A Receptor Ligand, 11C-Preladenant, in Healthy Human Subjects
- Initial Evaluation of 11C-Preladenant 1 (Journal of Nuclear Medicine) Title
- Recent Developments in Adenosine Receptor Ligands and Their Potential As Novel Drugs☆
- Fluorinated Adenosine A2A Receptor Antagonists Inspired by Preladenant As Potential Cancer Immunotherapeutics
- Adenosine 2A Receptor Occupancy by Tozadenant and Preladenant in Rhesus Monkeys
- Distinct P2Y Receptors Mediate Extension and Retraction of Microglial Processes in Epileptic and Peri-Tumoral Human Tissue
- Focusing on Adenosine Receptors As a Potential Targeted Therapy in Human Diseases
- Adenosine Receptor P1 Receptor
- INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri